“…Thus, for example, early studies perhaps surprisingly reported that miR-155 plays a joint-protective role in RA SFs, having been associated with downregulation of MMP1 and MMP3, mediators that promote SF proliferation and invasion, as well as bone destruction 35, 36, 38, 39, 46 . However, although these studies also indicated that miR-155 did not impact on MMP9 or MMP13 expression or modulate spontaneous or stimulated (TLR ligands/cytokines) TGF β or IL-6 production 41, 47 , more recent work has identified a key role for this miR in driving (spontaneous and TNF α -stimulated) pathogenic responses (proliferation as well as IL-1 β and IL-6 production) via downregulation of its target FOXO3 48–50 , which acts to suppress these functional outcomes in RA-SFs 51 . Thus, given the interactions of miR-155 with multiple TLR and cytokine (IL-1 β , IL-10, IL-17, TNF α , GM-CSF) pathways implicated in regulating arthritogenesis 38, 39 , we further investigated the role of this element in SF pathogenesis and ES-62-mediated protection.…”